Ly Maria, Yu Gary Z, Jahromi Amin Haghighat
Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, Missouri, USA.
Radiology, Division of Nuclear Medicine, Mallinckrodt Institute of Radiology, Washington University School of Medicine in St. Louis, 510 South Kingshighway Blvd, Campus Box 8223, St Louis, Missouri, 63110, USA.
EJNMMI Rep. 2025 Mar 24;9(1):10. doi: 10.1186/s41824-024-00231-7.
Capivasertib has emerged as a promising treatment for advanced breast and prostate cancer. Here, we report two cases of metastatic breast cancer patients who developed splenic hypermetabolism on [18 F]-FDG PET/CT following treatment with capivasertib. To our knowledge, these are the first documented instances of this treatment-related phenomenon. Although the mechanism behind this side effect remains unclear, these cases highlight an important imaging phenomenon that radiologists should consider when interpreting [18 F]-FDG PET/CT scans in patients treated with capivasertib.
卡匹西利已成为晚期乳腺癌和前列腺癌的一种有前景的治疗方法。在此，我们报告两例转移性乳腺癌患者，她们在接受卡匹西利治疗后，[18F]-FDG PET/CT显示脾脏代谢亢进。据我们所知，这些是这种治疗相关现象的首例记录病例。尽管这种副作用背后的机制尚不清楚，但这些病例突出了一种重要的影像学现象，放射科医生在解读接受卡匹西利治疗患者的[18F]-FDG PET/CT扫描时应予以考虑。
